What is IFA Diety AP 20mg?
IFA Diety AP 20mg is indicated as auxiliary in the treatment of exogenous obesity associated with a hypocaloric dietary regimen.
IFA Diety AP 20mg is a non-amphetamine anorexigen, sympathomimetic amine, derived from phenylisopropylamine with lipolytic and central action on hypothalamic appetite regulating centers.
When this IFA Diety AP 20mg applied simultaneously with:
– drugs inhibiting isoenzyme CYP3A4 (ketoconazole, erythromycin, troleandomycin, cyclosporine) increased plasma concentrations of metabolites of sibutramine, slightly increased the interval of QT.
– rifampin, phenytoin, carbamazepine, phenobarbital, dexamethasone, macrolide antibiotics may accelerate the metabolism of this medication.
– selective serotonin reuptake inhibitors (citalopram, fluoxetine, paroxetine, sertraline), agonist 5-HT1-receptors, derivatives of ergot alkaloids, opioids, centrally acting antitussives increases the risk of serotonin syndrome. You may need another drug like Acxion Fentermina.
Warnings and precautions
Risk of producing dependence and in certain cases psychic disorders in tto. chronic (4-5 months); interrupt the tto. if tolerance appears; do not exceed the recommended dose; control the p.c. of the patient and suppress the tto. if the descent of p.c. is very fast; It is not a substitute for a well-planned diet.
Dosage IFA Diety AP
The initial dose is 10 mg / day. With lack of effectiveness when used in this dose (weight loss less than 2 kg for 4 weeks) and if tolerated the dose can be increased to 15 mg / day.
If no effect when Ifa Diety Getz Pharma used in doses of 15 mg / day (weight loss less than 2 kg per 4 weeks), this drug should be discontinued.
In patients not adequately responding to treatment, that is who within 3 months can not reach the level of 5% weight loss from baseline, the duration of use this medication should not exceed 3 months.
The course of treatment is not more than 1 year since no data on efficacy and safety of longer use.
Do not use sibutramine, if after made weight loss achieved in the course of further therapy, the patient again adds to the weight of 3 kg or more.